The Latest Breaking News from Guggenheim

SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target.  The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity.  It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted).  The outlook is supported by…

Guggenheim has decided to maintain its Buy rating of Meta Platforms (NASDAQ:FB) and lower its price target from $275.00 to $250.00. Shares of Meta Platforms are trading down 2.94% over the last 24 hours, at $196.67 per share.

Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Teladoc Health Inc (NYSE: TDOC) is a market leader in digital services, and the breadth of its services is unmatched, according to Guggenheim. The Teladoc Health Analyst: Sandy Draper initiated coverage of Teladoc Health with a Buy rating and $96 price target.

Upgrades

Upgrades

ESS Tech Inc (NYSE:GWH) coverage has been initiated with a Buy rating and a price target of $10 (implying an upside of 82.5%) by Guggenheim analyst Joseph Osha. The analyst cites ESS as one of a large group of companies over the past two decades aiming to make flow batteries work commercially. Osha views ESS…

Upgrades

Analysts lowered their price target on Domino's Pizza Inc (NYSE:DPZ) following the company's Q4 results. Citi analyst Sergio Matsumoto lowered the price target to $480 (18% upside) from $540 and kept a Neutral rating on the shares. The analyst cited forecast decreases and market conditions for the reduced price target. Barclays analyst Jeffrey Bernstein lowered…